

CACI – Psoriasis Worksheet

(Updated 11/27/2024)

To determine the applicant's eligibility for certification, the AME must review a [current, detailed Clinical Progress Note](#) generated from a clinic visit with the treating physician or specialist **no more than 90 days prior** to the AME exam. If the applicant **meets ALL the acceptable certification criteria** listed below, the AME can issue. Applicants for first- or second- class must provide this information annually; applicants for third-class must provide the information with each required exam.

| AME MUST REVIEW | ACCEPTABLE CERTIFICATION CRITERIA |
|---|---|
| A current, detailed Clinical Progress Note from the treating physician | <input type="checkbox"/> Condition is stable with NO systemic symptoms and NO limitation to strength, function, or range of motion which would interfere with flight duties. <input type="checkbox"/> Severity is mild to moderate. NOTE: If co-morbid conditions are present, see corresponding page. If psoriatic arthritis, see arthritis page. |
| Causes | <input type="checkbox"/> Most subtypes to include: guttate psoriasis, plaque psoriasis. Not acceptable: pustular psoriasis, erythrodermic psoriasis. |
| Lab | <input type="checkbox"/> If on methotrexate: Normal CBC, Liver Function Test, and Creatinine within the past 90 days. OR <input type="checkbox"/> Not taking methotrexate |
| Medications for condition Combinations acceptable for CACI Include: <ul style="list-style-type: none"> • Topical medication + • Methotrexate + • Any single agent listed KEY: Interleukin Inhibitors (IL) Phosphodiesterase-4 Enzyme Inhibitor (PDE4) Tumor necrosis factor inhibitors (TNF) *Biologics do not have generic; they have biosimilar. | <input type="checkbox"/> Topical medication(s) and/or <input type="checkbox"/> methotrexate (Trexall) and/or <input type="checkbox"/> Any single medication listed below after a 2-week ground trial and: <ul style="list-style-type: none"> • No post-dose observation time: <ul style="list-style-type: none"> ▪ apremilast (Otezla) - PD4E • 4-hour post-dose observation time: <ul style="list-style-type: none"> ▪ adalimumab (Humira or FDA approved biosimilar*) - TNF ▪ certolizumab (Cimzia) - TNF ▪ etanercept (Enbrel) - TNF ▪ guselkumab (Tremfya) - IL ▪ ixekizumab (Taltz) - IL ▪ risankizumab (Skyrizi) - IL ▪ secukinumab (Cosentyx) – IL ▪ tildrakizumab (Ilumya) - IL ▪ ustekinumab (Stelara) - IL • 24-hour post-dose observation time: <ul style="list-style-type: none"> ▪ infliximab (Inflect; Remicade; Renflexis) - TNF |

AME MUST NOTE in Block 60 one of the following:

- ☐ CACI qualified Psoriasis. (Documents do not need to be submitted to the FAA.)
- ☐ Has current OR previous SI/AASI but now CACI qualified Psoriasis.
- ☐ NOT CACI qualified Psoriasis. I have deferred. (Submit supporting documents.)